Lupin - nilotinib Interaction Details | HelloPharmacist
Evidence-based interaction details between nilotinib (brand name(s): Tasigna) and Lupin, including interaction severity and how likely the interaction is to occur.
NILOTINIB 300mg PO TWICE daily. Consider increase dose to 400mg TWICE daily if suboptimal response (off-label). For patients in sustained MMR and troublesome side effects, dose can be reduced to 400mg once daily. Resistant CML NILOTINIB 400 mg PO TWICE daily Dose should be taken approximately 12 hours apart and must not be taken with food. No food
尼洛替尼 - 百度百科
瑞士在全世界范围内首次批准诺华公司的强效和新颖的靶向治疗药尼罗替尼口服片剂(商品名：Tasigna)上市，用于治疗对甲磺 酸伊马替尼(商品名：Glivec)治疗无效或不能耐受威胁生命的血癌慢性粒细胞白血病(CML)。
Nilotinib Accord | European Medicines Agency (EMA)
2024年6月28日 · Nilotinib Accord is a medicine for treating chronic myelogenous leukaemia (CML) – a blood cancer – in patients who have been newly diagnosed or who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them.
尼洛替尼 - 维基百科，自由的百科全书
尼洛替尼（英語： Nilotinib ），是由瑞士 諾華公司研製銷售 [1] ，治療慢性骨髓性白血病的第二代/新一代標靶藥物 [2] 。 在一项I型临床试验中，尼洛替尼被发现，其也因其临床编号称之为 AMN107 。
Nilotinib - Wikipedia
Nilotinib, sold under the brand name Tasigna among others, is a anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [3] [7] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [3] [7] [8] It is ...
Nilotinib: A second-generation tyrosine kinase inhibitor for the ...
2008年11月1日 · Results: Nilotinib is an orally bioavailable derivative of imatinib with improved specificity toward the breakpoint cluster region-Abelson murine leukemia ( bcr-abl) viral protooncogene. In preclinical studies, nilotinib was found to have activity against 32 of 33 imatinib-resistant bcr-abl mutations, but not against the T3151 mutation.
Tasigna (nilotinib) is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or...
Nilotinib: from animal-based studies to clinical investigation in ...
Nilotinib was approved by the US FDA in 2010 and was initially authorized for the treatment of adults with chronic myeloid leukemia positive for the Philadelphia chromosome. The pharmacokinetic evidence proved that Nilotinib crosses the blood-brain barrier and targets c-Abl and discoidin domain receptors efficiently.
Nilotinib Uses, Side Effects & Warnings - Drugs.com
2024年3月15日 · Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old. Nilotinib is usually given after other treatments have failed. Nilotinib may also be used for purposes not listed in this medication guide.